ANTIPHOSPHOLIPID ANTIBODY-PRODUCTION DURING MEDITERRANEAN SPOTTED-FEVER

被引：6

作者：

SOTTO, A

BERARD, M

BESSIS, D

PORNEUF, M

JOURDAN, J

BOFFA, MC

机构：

[1] Service de Medecine Interne B. Hôpital Carémean, Nǐmes

[2] INSERVM U 353, Hôpital Saint-Louis, Paris

[3] Service de Dermatologie-Phléhologie, Hôpital Saint-Charles, Montpellier

来源：

AUTOIMMUNITY | 1995年 / 21卷 / 02期

关键词：

MEDITERRANEAN SPOTTED FEVER; RICKETTSIA CONORII; ANTIPHOSPHOLIPID ANTIBODIES; ANTIPHOSPHATIDYLETHANOLAMINE ANTIBODIES;

D O I：

10.3109/08916939508993359

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Antiphospholipid antibodies (aPLA) were discovered during the course of Mediterranean spotted fever (MSF) caused by Rickettsia conorii and characterized by endothelial cell (EC) damage resulting from this organism's tropism for EC. In two MSF patients, two types of aPLA were identified: antiphosphatidylethanolamine antibodies detected by immunological methods and lupus anticoagulant detected by clotting assays. The persistence of both aPLA for several months after the acute phase and clinical recovery might correspond to a durable immunological response to membrane damage of EC caused by R. conorii. Their possible role in the pathophysiology of microthrombi formation observed during MSF remains to be elucidated in a study on a larger number of patients.

引用

页码：123 / 126

页数：4

共 22 条

[1]

Gomez-Mateos J.M., Lozano de Leon F., Pineda J.A., Diaz-Torres M.A., Flebitis de miembros inferiores: complicacion de la fiebre botonosa mediterranca, Med. Clin., 87, (1986)

[2]

Vicente V., Moraleda J.M., Herrero I., Ruiz R., Hipercoagulabilidad y fiebre exantematica mediterranea, Med. Clin., 97, (1991)

[3]

Vicente V., Alberca I., Ruiz R., Herrero I., Gonzalez R., Portugal J., Coagulation abnormalities in patients with Mediterranean spotted fever, J. Infect. Dis., 153, pp. 128-131, (1986)

[4]

Vicente V., Espana F., Tabernero D., Estelles A., Aznar J., Hendl S., Griffin J.H., Evidence of activation of the protein C pathway during acute vascular damage induced by Mediterranean spotted fever, Blood, 78, pp. 416-422, (1991)

[5]

George F., Brouqui P., Boffa M.C., Mutin M., Drancourt M., Brisson C., Raoult D., Sampol J., Demonstration of Rickettsia conorii-induced cndothelial injury in vivo by measuring circulating endothelial cells, thrombomodulin, and von Willebrand factor in patients with Mediterranean spotted fever, Blood, 82, pp. 2109-2116, (1993)

[6]

Selva A., Porcel J.M., Ordi J., Juste C., Monegal F., Martinez X., Barquinero J., Anticardiolipin antibodies and rickettsial diseases, Clin. Exp. Rheumatol., 8, (1990)

[7]

Monegal-Ferrand J., Ordi Ros J., Arderiu Freixa A., Fernandez Cortijo J., Barquinero Manez J., Vilardell Tarres M., Anticorps antiphospholipide et rickettisioses, Rev. Med. Interne., 10, pp. 576-577, (1989)

[8]

Sanmarco M., Tissot Dupont H., Soler C., Guingand C., Raoult D., Bernard D., Anticardiolipin antibodies in infectious diseases: a comparison between Q fever and Mediterranean spotted fever, Lupus, 3, (1994)

[9]

Berard M., Boffa M.C., Karmochkine M., Aillaud M.F., Juhan-Vague I., Frances C., Piette J.C., Harle J.R., Plasma reactivity to hexagonal II phase phosphatidylethanolamine is more frequently associated with lupus anticoagulant than with antiphosphatidylcthanolamine, J. Lab. Clin. Med., 122, pp. 601-605, (1993)

[10]

Triplett D.A., Barna L.K., Unger G.A., A hexagonal phase phospholipid neutralization assay for lupus anticoagulant identification, Thromb. Haemostas., 70, pp. 787-793, (1993)

← 1 2 3 →